Results 171 to 180 of about 55,815 (216)

LncRNA LMCD1-AS1 Interacts with PHF8 to Promote Hepatocellular Carcinoma Resistance to Multikinase Inhibitors. [PDF]

Int J Biol Sci
Yang X, Song S, Ye T, Zhang X, Yang Z, Mi Y, Shen Y, Zhang Y, Liu J, Ye Q.   +9 more
europepmc   +1 more source

Study on the effect of Ursolic acid on liver cancer cells using z-vad-fmk and ROS inhibitors. [PDF]

Cytotechnology
Xu M, Wu J, Huang Z, Shi M, Fu T, Lin A, Zhang G.   +6 more
europepmc   +1 more source

Selinexor enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by regulating the BAX/Bcl-2/PUMA apoptotic pathway and the XPO1/p27 cell cycle pathway. [PDF]

Front Oncol
Du S, Wang L, Chen C, Sun Y, Liu Q, Shi J, Zhang F, Wang K, Cui C.   +8 more
europepmc   +1 more source

Evaluating patient-reported outcomes in randomized controlled trials of targeted therapy and/or immunotherapy for liver cancer: a scoping review. [PDF]

Front Oncol
Ren L, Liu Y, Li S, Yue S, Su C, Wang J, Zhang Y.   +6 more
europepmc   +1 more source

First-line therapies for unresectable hepatocellular carcinoma: a network meta-analysis of immune checkpoint inhibitors and transarterial therapies based on 35 randomized trials. [PDF]

Front Oncol
Zhang H, Zhou S, Dai J, Huang H, Yang B, Huang W, Tang D.   +6 more
europepmc   +1 more source

Reversible sorafenib-associated coagulopathy identified by viscoelastic testing in a dog with intranasal sarcoma. [PDF]

J Vet Intern Med
Kim D, Jo Y, Kim S, Choi M, Kim Y.
europepmc   +1 more source

Therapeutic Targeting of miR-21 Restores SASH1 and Sensitizes HBV-HCC to Sorafenib. [PDF]

Cancers (Basel)
Han K, Jwa EK, Ha S, Kim J, Lee R, Lee E, Kang S, Kim HO, Kwon H, Jung DH, Yoon YI, Song GW, Park GC, Kim TW, Namgoon JM, Hwang S, Tak E, Lee SG.   +17 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Sorafenib

Reactions Weekly, 2019
Sorafenib (BAY-43-9006), marketed by Bayer as Nexavar® (USA), is anticancer drug approved by US-FDA for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. Sorafenib inhibited tumor growth and angiogenesis through targeting both the RAF/MEK/ERK pathway and receptor tyrosine kinases.
Ahmed A, Abdelgalil, Hamad M, Alkahtani, Fahad I, Al-Jenoobi   +2 more
openaire   +3 more sources